Genflow Biosciences is an anti-aging company looking to use gene therapy to address the challenge of improving the lifespan of humans and dogs. I find it both interesting and a bit odd to include dogs here, but if they can use the same solution for both then why not.
Their mission states:
To deliver therapeutics that potentially halt or slow the ageing process in humans and dogs
Interestingly Genflow Biosciences have selected a specific gene named SIRT6, which they have used as a target to develop compounds. They already completed preclinical trials for their leading compound, which they report has shown encouraging results.
Feel welcome to share your own thoughts on this company in the comment section below. I will be happy to discuss and learn more about how you see their potential in this field.
The solution
According to their pipeline Genflow Biosciences have 3 compounds of interest that they are investigating. For the two compounds addressing humans the target gene is named SIRT6. I added the below image of their pipeline from their official website – you can find a link at the end of this post.
The leading compound here is GF-1002, which is the first one listed and it has already shown promising preclinical results. The next step from here according to Genflow Biosciences is a first in human proof of concept phase I/II clinical trial in NASH (non-alcoholic steatohepatitis) patients. The reason behind looking at this specific segment is that the preclinical results highlighted the adipogenic, anti-fibrotic, and anti-tumoral effects of the GF-1002 compound. These traits positions the compound as a potential candidate for targeting and treating NASH. This is the extend of information we have on their lead compound so far, but we hope to hear more when the trial results come out.
The second compound on the pipeline is also targeting humans and associated with the SIRT6 gene. It is known as GF-3001, and is currently in the development phase. According to Genflow Biosciences they are already planning a clinical phase I/II trial for patients with Werner Syndrome for this compound. The reason for looking into Werner Syndrome specifically is that this disease serves as a model for studying premature aging in humans, and Genflow Biosciences believe that this study can provide insights into the aging process that may be of significant value. Although, I assume they will have to complete preclinical studies before moving on to this step, and as such it will take some time before this study can be conducted.
For the third and last compound we do not know more than what is simply stated in the above pipeline image. Hopefully they will be ready to disclose more information about this soon.
The company
Genflow Biosciences is headquartered in London, UK, and they have research and development facilities in Belgium as well as a US office in Cambridge, MA. It was founded in 2020.
In terms of investments we know that there was a seed round that closed in January of 2021. One of the investors of this seed round is a venture capital called Longevitytech.fund, however, the amount invested is not disclosed.
Also, Genflow Biosciences is listed on the London Stock Exchange (LSE) with the ticker GENF. You can find them through this link.
Without knowing the above investor’s capital injection we have to assume that most of the company capital is derived from their stock market listing. They have been listed since January 2022, so it would make sense that the capital injection following the VC would come from this listing.
Although, investors do not seem to have much faith in the company as the stock has been on a significant decline since launch – dropping from trading at some £12 per share when entering the market to around £1.5 at the beginning of 2024. The shares are in this period down by around 87%, which is very disheartening. Hopefully they can do something to rectify the situation and restore the investor’s confidence in them as a company with a solution that will enhance our future.
I added a link to their official website in the below if you want to read more, but fair warning their website is incredibly slow. Seems strange to me that they are not looking to optimize their website performance if they want to increase their visibility and presence in this field – not least to attract potential investors.
Read about more anti-aging companies on this website through this link.
